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Abstract
AIM
To determine the clinical effectiveness of nutritional 
counseling on reduction of non-alcoholic fatty liver 
disease (NAFLD) severity, weight loss, metabolic and 
anthropometric indexes and liver enzymes.
METHODS
Forty-six adults with NAFLD received a 6-mo clinical and 
a dietary intervention (based on Mediterranean diet) 
carried out respectively by a gastroenterologist and 
a nutritionist with counseling license. The counseling 
process consisted of monthly meeting (about 45 min 
each). The effect of the treatment was evaluated 
monitoring liver enzymes, metabolic parameters, 
cardiovascular risk indexes, NAFLD severity [assessed 
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by ultrasound (US)] and related indexes. All parameters 
were assessed at baseline. Biochemistry was also 
assessed at mid- and end-interventions and US was 
repeated at end-intervention.
RESULTS
The percentage of patients with steatosis grade equal 
or higher than 2 was reduced from 93% to 48% and 
steatosis regressed in 9 patients (20%). At the end of 
the treatment the end-point concerning the weight (i.e. , 
a 7% weight reduction or achievement/maintenance 
of normal weight) was accomplished by 25 out of 46 
patients (i.e. , 54.3%). As far as the liver enzymes is 
concerned, all three liver enzymes significantly decrease 
during the treatment the normalization was particularly 
evident for the ALT enzyme (altered values reduced 
from 67% down to 11%). Several parameters, i.e. , 
BMI, waist circumference, waist-to-hip ratio, AST, ALT, 
GGT, HDL, serum glucose, Tot-Chol/HDL, LDL/HDL, TG/
HDL, AIP, HOMA, FLI, Kotronen index, VAI, NAFLD liver 
fat score and LAP, showed a significant improvement (P  
< 0.01) between baseline and end-treatment.
CONCLUSION
Outcomes of this study further strengthen the hypo-
thesis that MedDiet and more active lifestyle can be 
considered a safe therapeutic approach for reducing 
risk and severity of NAFLD and related disease states. 
The proposed approach may be proposed as a valid 
and recommended approach for improving the clinical 
profile of NAFLD patients.
Key words: Non-alcoholic fatty liver disease; Non-
alcoholic steatohepatitis; Mediterranean diet; Metabolic 
syndrome; Therapeutic approach; Counseling; Diet; 
Life-style
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Most recent advances in the management 
and treatment of Non-alcoholic fatty liver disease 
(NAFLD) show that a multifaceted approach is likely 
to achieve the best outcomes. Our study evaluates 
the effectiveness of 6-mo multidisciplinary approach 
jointly carried out by a gastroenterologist and a 
nutritionist with counseling license. The approach was 
effective on the reduction of NAFLD severity, weight, 
anthropometric indexes, cardiovascular disease risk 
factors and the normalization of metabolic index, as 
well as liver enzymes. This study strengthens the 
hypothesis that MedDiet and more active lifestyle can 
be considered a safe therapeutic approach for reducing 
severity of NAFLD.
Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De 
Lorenzo A. Effect of a counseling-supported treatment with the 
Mediterranean diet and physical activity on the severity of the 
non-alcoholic fatty liver disease. World J Gastroenterol 2017; 
23(17): 3150-3162  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i17/3150.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i17.3150
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a relevant 
issue in public health because represents a major cause 
of chronic liver diseases worldwide. Approximately 20% 
to 30% of adult population has NAFLD, making it the 
most common liver disease in developed countries[1,2]. 
NAFLD is the result of fat accumulation in the liver (with 
fat representing more than 5% of whole liver weight) 
in absence of excessive alcohol consumption (usually 
evaluated using thresholds of 20 and 30 g/d for women 
and men respectively[3].
NAFLD includes two pathologically distinct conditions 
with different prognoses: non-alcoholic fatty liver (NAFL) 
and non-alcoholic steatohepatitis (NASH); the latter 
covers a wide spectrum of disease severity, including 
fibrosis and cirrhosis and promoting hepatocellular 
carcinoma development[4].
NAFLD is a multifactorial disease and the exact 
mechanism is unknown. It is usually associated to 
one or more conditions that contribute to the meta-
bolic syndrome (MS) (diabetes mellitus, obesity, 
hypertension, and hyperlipidemia) and therefore is 
considered as its hepatic manifestation[5-9]. 
Several therapeutic interventions for NAFLD have 
been proposed over the last decades but any of 
these proved to be safe and effective[10,11]. Among 
therapeutic interventions there are weight reduction 
(e.g., low-calorie diet, exercise and bariatric surgery), 
insulin sensitizer agents and incretins, lipid lowering 
drugs (e.g., statins), antioxidants (e.g., vitamin E) and 
treatment of vitamin D3 deficiency[12]. Pharmacological 
therapies have not been always successful in reducing 
liver steatosis or inflammation[12,13]. On the other 
hand, other drugs, such as thiazolidinediones, have 
some success in improving liver histology but have 
undesirable side effects such as weight gain[14].
Epidemiological evidence suggests a tight relationship 
between unhealthy lifestyle (mainly related to diet and 
physical inactivity) and NAFLD (Zelber-Sagi et al[15], 
2011) and therefore there is a general consensus on 
considering healthy diet and regular physical activity as 
the cornerstones in the treatment of NAFLD[4,12,16]. In 
addition, these interventions have been demonstrated 
also effective for improving conditions of MS and the 
related risk of cardiovascular disease (CVD)[17].
So far several dietary models have been proposed 
for reducing severity and preventing NAFLD. Among 
these, the Mediterranean diet (MedDiet) can be 
considered one of the healthiest as its benefits are 
attributed to a lower incidence of chronic disease 
including CVD, obesity, cancers, and overall mortality 
demonstrating its safety, palatability and sustaina-
bility[18]. According to several studies carried out during 
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the last few years[19,20], the MedDiet resulted as the 
most effective for inducing weight loss together with 
beneficial effects on all the risk factors associated with 
MS and NAFLD as demonstrated in several[21] state 
that higher adherence to MedDiet seems to have a 
beneficial effect on the severity of disease in patients 
with NAFLD.
Increased routinary physical activity demonstrated 
to be beneficial in reducing the severity of NAFLD both 
associated to weight loss[22] or per se[23] and is well 
known for its beneficial effects on reducing risks of 
developing components of MS[24]. Some studies also 
showed that increased routinary physical activity[25] and 
cardiorespiratory fitness[26] are inversely associated with 
NAFLD. 
For all these reasons, a structured programme 
aimed at lifestyle changes towards healthy diet (with 
a 7%-10% weight loss in overweight/obese patients) 
and routinary physical activity is the most advisable for 
the treatment of NAFLD[4].
Nonetheless, lifestyle modification is usually 
difficult to achieve and maintain, above all in the long 
term, for a variety of reasons[27,28]. In particular, many 
patients have difficulty to find motivation to change 
their unhealthy lifestyle although most of them are well 
aware of the importance of healthy diet and habitual 
physical activity. Centis et al[29] report NAFLD cases have 
scarce readiness to physical activity change, and 50% 
of cases were classified in either the precontemplation 
or contemplation stage of change, i.e., refractory to 
increase exercise.
For these reasons there, in order to increase the 
success of the approach laying on lifestyle change 
towards a healthy diet and habitual physical activity, 
there is the need to move from the traditional pres-
criptive approach to an individualized, multidisciplinary, 
empowerment-based intervention, tailored on patients’ 
preferences.
In this study we tested the effectiveness of nutri-
tional counseling on reduction of NAFLD severity, 
weight loss, metabolic and anthropometric indexes and 
liver enzymes. The approach was jointly carried out by 
a gastroenterologist and a nutritionist with counseling 
patent and was aimed at supporting patients to move 
toward a lifestyle including MedDiet-based dietary 
habits and regular physical activity.
MATERIALS AND METHODS
Study design and outcome measures
This observational study proposes a 6-mo interventions 
for treating patients with NAFLD. The approach is based 
on a clinical and a MedDiet-based dietary intervention 
carried out respectively by a gastroenterologist and a 
nutritionist with counseling license. The innovation of 
this approach is the use of the nutritional counseling 
to strengthen participants’ motivation and increase 
adherence to healthy lifestyle recommendations and, 
at the same time, educating and promoting lifelong 
healthy eating habits.
Prospective participants underwent a thorough 
screening visit and a detailed analysis to asses 
clinical and health-related conditions, biochemistry, 
dietary habits, physical activity level, lifestyle and 
anthropometry. The nutritionist also provided patients 
with indications for drafting the food and physical 
activity diaries (including 3 weekdays and 1 weekend).
Eligible participants underwent a second meeting 
(after 1 wk) with the nutritionist who gather drafted 
food and physical activity diaries (then used to check 
and further refine the outcomes of the first interview) 
and deliver to the participants written resources 
containing the food pyramid, healthy eating guidelines 
and tips, basic information on portion size, examples 
to reduce food intake (maximum calorie reduction, 
500 kcal/d) and dietary recommendations. These 
latter were specifically designed and tailored taking 
into account nutritional needs, diseases (if any), and 
other information and/or needs communicated during 
the first meeting and consisted of daily and weekly 
meal plans and suggestion for meals composition 
stimulating patients to self-arrange their diet according 
to the MedDiet. Within this meeting also starts the 
counseling process (see below).
During monthly meetings, carried out for the 
counseling process, the nutritionist also evaluates the 
adherence to the dietary recommendations, makes 
eventual adjustments, assesses anthropometry and 
assists participants in maintaining motivations. 
Biochemistry was assessed at mid- and end-
interventions (3 and 6 mo) and ultrasonography was 
repeated at end-intervention (6 mo).
The following end-points were set to assess the 
efficacy of the proposed approach: (1) reduction of 
at least 1 unit of steatosis grade; (2) A 7% weight 
reduction (in accordance to EASL-EASD-EASO, 2016[4]) 
or achievement/maintenance of normal weight; (3) 
Normalization or improvement of metabolic indexes 
[Total cholesterol (Tot-Chol), HDL-cholesterol, LDL-
cholesterol, serum glucose, triglycerides (TG)]; and (4) 
normalization or improvement of ALT, AST, GGT.
Participant recruitment and eligibility
For this study were recruited 46 adult (26-71 years 
old) patients with recent (within the previous 6 
mo) diagnosis of NAFLD, who visited the outpatient 
liver clinics of the at Clinical Gastroenterology Unit, 
University Hospital Careggi between February 2016 
and August 2016.
The diagnosis was based on clinical, ultrasono-
graphic and laboratory values, after exclusion of any 
other cause of chronic liver disease (hepatitis B and C 
virus, autoimmune and metabolic disease) and alcohol 
intake not exceeding 20 g/d (confirmed by relatives).
Participants were excluded if they: (1) refused or 
were unable to give informed consent to participate 
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and traditional, local, eco-friendly and biodiverse 
products.
Anthropometry, biochemistry and inflammatory markers
Weight, height, waist circumference, hip circumference, 
BMI were taken using standard procedures by the 
nutritionist.
Liver enzymes (AST, ALT, alkaline phosphatase, 
GGT), Tot-Chol, HDL-cholesterol, LDL-cholesterol, 
serum glucose, TG, insulin resistance index HOMA-Ir 
and QUICKI were acquired or calculated from medical 
records delivered by participants.
The following indexes related to NAFLD were 
also calculated: the Kotronen index and NAFLD liver 
fat score[33], the Fatty Liver Index (FLI)[34] and the 
Visceral Adipose Index (VAI)[35]. Kotronen index is 
used as predictor of liver fat percentage. NAFLD liver 
fat score allows identification of NAFLD using easily 
available clinical and laboratory data. FLI measures the 
probability of significant steatosis (values < 30 rule out 
and values ≥ 60 rule in fatty liver). VAI is an indicator 
of visceral fat associated with cardiometabolic risk.
In order to make an enlarged clinical and nutritional 
evaluation of participants were estimated some 
cardiovascular risk indexes [Tot-Chol/HDL, LDL/HDL, 
TG/HDL and atherogenic index of plasma (AIP)], 
systemic inflammation indexes [platelet to lymphocyte 
ratio (PLr) and neutrophil to lymphocyte ratio (NLr)], 
a marker of MS [lipid accumulation product (LAP)] and 
two indexes used to assess advanced liver fibrosis in 
patients with NAFLD (BArD and NAFLD).
Assessment of the adherence to the MedDiet
The level of adherence to the Mediterranean dietary 
pattern was evaluated using the Mediterranean Diet 
Score (MedDietScore) as defined by Panagiotakos 
et al[36]. Briefly, for the score calculation, the con-
sumption of food items from 9 food groups (non-
refined starchy food, potatoes, fruit, vegetables, 
legumes, fish, meat and meat products, poultry, 
and full fat dairy products), as well as olive oil, and 
alcoholic beverages, have to be taken into account. For 
each food item a score is assigned on the basis of the 
frequency of consumption. For food items close to the 
MedDiet the higher the frequency the higher the score 
and viceversa for food items that are away from the 
MedDiet. For further information, refer to Panagiotakos 
et al[36].
Counseling process
The counseling is an ongoing process taking all the 
intervention’s duration and in each meeting the 
nutritionist and the patient discuss the opportunity to 
reevaluate goals and strategies for achieving set goals. 
During the counseling process the nutritionist and the 
patient work together to identify areas where change 
is needed, prioritize changes, and problem-solve as to 
how to make the changes.
in the study; (2) had evidence of advanced liver 
disease (cirrhosis, hepatocellular carcinoma); (3) 
had clinically relevant pathologies (e.g., pulmonary, 
gastro-intestinal, renal, metabolic, haematological, 
neurological, psychiatric, systemic or any acute 
infectious disease or signs of acute illness); and 
(4) had contraindications included bulimia nervosa, 
substance abuse, clinically significant depression, or 
current psychiatric care.
The study was approved by the appropriate Ethics 
Committee (“Centro, rC” 30.11.02.2016) and was 
carried out in accordance with the declaration of 
Helsinki[30]. All patients gave their written informed 
consent before the recruitment.
Dietary intervention
The dietary intervention was based on the MedDiet 
which was firstly introduced and described by Keys 
et al in “The Seven Countries Study”. After that study 
several other studies confirmed the beneficial effects 
and outcomes of the MedDiet on the health mainly 
reducing mortality, cardiovascular disease risk factors 
and cancer (Sofi et al[18], 2010).
The MedDiet is based on a balanced use of foods 
rich in fiber, antioxidants and unsaturated fats, a 
healthy approach designed to reduce the consump-
tion of animal fats and cholesterol in a diet with an 
appropriate balance between energy intake and ex-
penditure[31]. Therefore the MedDiet is characterized 
by high consumption of vegetables, fruits, non-refined 
cereals, legumes and potatoes, moderate consumption 
of fish and poultry and low consumption of full fat 
dairies, red meat and its products and homemade 
sweets. Olive oil is the basic source of fat used for food 
preparation and during consumption. Meals are often 
accompanied by low-to-moderate amounts of wine. 
The relationships between the macronutrient in the 
MedDiet is 55%-60% of carbohydrates of which 80% 
complex carbohydrates (bread, pasta, rice), 10%-15% 
of proteins about 60% of animal origin (especially 
white meat, fish), 25%-30% fat (mostly olive oil)[31]. 
The MedDiet has also a graphic representation 
which is typically a pyramid whose most updated 
version is described by[32]. The graphic representation 
follows the previous pattern: at the base, food items 
that should sustain the diet and provide the highest 
energy intake, and at the upper levels, foods to be 
eaten in moderate amounts such as those of animal 
origin and/or rich in sugars and fats that should be 
eaten in moderation and some of them left for special 
occasions[32].
Along with recommendations regarding the pro-
portion and frequency of food consumption, the 
incorporation of cultural and lifestyle elements is one 
of the innovations of the latest version of the pyramid. 
These concepts represented outside of the pyramid, 
but at its base, are: moderation, socialization, culinary 
activities, physical activity, adequate rest, seasonality 
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In this study the counseling process was individually-
tailored and consisted of 6 monthly 30-45 min face-
to face meetings aimed to enhance internal motivation 
and facilitate behavior change concerning both diet 
and lifestyle (in terms of physical activity level). The 
techniques used were mainly: motivational interviewing, 
active listening and rogers/PNL/Gestalt techniques.
As far as dietary habits, patients were stimulated 
in order to strengthen their capability to successfully 
follow and adhered to the recommendations contained 
in written resources delivered and dietary intervention 
as described in the previous section.
The nutritionist initially explains to the patient that 
making dietary change should be a gradual process 
and that the truth challenge is not in making the initial 
dietary changes, but in maintaining them over the long 
term. The process may start with one or two easier 
dietary changes in the first few weeks and gradually 
make additional or more difficult changes over several 
weeks or months. In addition, factors affecting food 
decisions (ethnic background, religion, group affiliation, 
socioeconomic status) are taken into account during 
meetings.
The nutritionist and patient also set behavior-
oriented goals together focusing on the behaviors 
needed to achieve the desired dietary change, not on 
an absolute value, such as achieving a certain body 
weight. Once the needed changes and goals have 
been identified, the patient and nutrition counselor 
think through potential problems that may arise (e.g., 
purchasing different foods, planning ahead for social 
events, or bringing special foods to work).
As far as the physical activity is concerned, the 
counseling approach was mainly used to stimulate 
patients to increase their physical activity. A motivational 
method instead of the common prescriptive one, 
was used to favor a more active lifestyle taking an 
incremental approach i.e., trying to increase the general 
level of activity throughout the day and every day up 
to a level sustainable and compatible with physical 
conditions and time available.
During the meetings patients and the nutritional 
counselor tried to set achievable goals tailored on the 
physical conditions of single patient. People with (very) 
limited physical activity level were stimulated to start 
identifying and putting in practice ways to increase 
their physical activity. For example, elder people and 
obese were stimulated to identify daily activities that 
could increase their physical activity (e.g., walking, 
riding the bike, get off the bus one stop earlier, walk up 
the stairs instead of taking the elevator, walk the dog, 
walk with their children, etc.). All patients without any 
physical constrain were stimulated to identify and take 
up/maintain regular physical activity. For these latter 
patients, the final goal was a habitual physical activity 
workload > 20 METs/h per week (corresponding to 
3-h/wk moderate-intense physical activity) which was 
used in the study of Montesi et al[37].
Ultrasound assessment of NAFLD
Severity of NAFLD was assessed by ultrasound (US) 
(Ultrasound alpha 7, Hitachi Aloka Medical America, 
Inc.). The US results were interpreted always by the 
same investigator well experienced in performing 
and interpreting hepatic US and blinded to the clinical 
data. The sonographic findings that were specifically 
evaluated included the hepato-renal contrast, bright 
hepatic echoes, deep attenuation, vessel blurring 
and non-specific findings of heterogeneous echoes. 
The degree of steatosis during US was graded as ab-
sent (0), mild (1), moderate (2) and severe (3). The 
liver image was assessed to be normal if the texture 
was homogenous, exhibited fine level echoes and 
isoechoic compared to the renal cortex and adequate 
visualization of the hepatic vessels and diaphragm 
(grade 0). Criteria for determining the degree of 
liver steatosis included: presence of bright echoes 
or increased hepato-renal contrast indicative of mild 
steatosis (grade 1); presence of both bright echoes 
and increased hepato-renal contrast as well as vessel 
blurring indicative of moderate steatosis (grade 2); 
severe steatosis was considered to be present when 
in addition to the criteria for moderate steatosis, there 
was evidence of posterior beam attenuation and non-
visualization of the diaphragm (grade 3)[38]. 
Statistical analysis
Microsoft Office Excel 2007 and IBM SPSS Statistics 
for Windows 20.0.0 were used for all the statistical 
calculations. Continuous variables are presented as 
mean values ± SD, while categorical variables are 
presented as frequencies. Unpaired t-test (2-tail) 
was used to test differences between baseline, mid-
treatment (3 mo) and end-treatment (6 mo). Fisher’s 
distribution was used to assess significance of linear 
regression between steatosis grade and anthropometric, 
clinical and metabolic parameters at baseline (BL), 
mid-treatment (3 mo) and end-treatment (6 mo). All 
reported P values were based on two-sided tests and 
compared to a significance level of 5% (P < 0.05).
RESULTS
Patients’ characteristics
The screening visit was carried out on 82 potential 
participants, out of which 36 excluded and 46 recruited. 
All patients were Italian and Caucasian ethnicity. Table 1 
summarizes characteristics of patients recruited for the 
study in terms of gender, age, anthropometry, BMI and 
steatosis grade, components of MS[39], MedDietScore, 
physical activity and smoking habits.
Table 2 focuses on 12 patients with MS showing 
the number of patients affected by each component. 
At the moment of the inclusion in the study, 5 out of 
12 patients with MS were under treatment for one or 
more components of the MS (5 for hypertension and 2 
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also for dyslipidaemia) and 4 patients without MS were 
under treatment for the type 2 diabetes. In all cases 
the treatment was maintained unaltered throughout 
the study.
Effect of the treatment on steatosis grade, weight and 
liver enzymes
At the baseline steatosis was grade 1 for 3 patients 
(7%), grade 2 for 19 patients (41%) and grade 3 for 24 
patients (52%). At the end of the treatment steatosis 
was regressed in 9 patients (20%), 15 patients had a 
grade 1 (33%), 18 patients a grade 2 (39%) and only 4 
patients still had a grade 3 (9%). Distribution of patients 
among steatosis grade at baseline and end-treatment 
is shown in Figure 1. Percentage of patients with severe 
steatosis was slightly higher than 50% at baseline and 
below 10% after the treatment. 
At baseline 35 patients were overweight (BMI > 25) 
and 11 had normal weight. At the end of the treatment 
patients with a normal weight increased to 20. Among 
patients overweight at baseline, 12 achieved a weight 
reduction of at least 7% and in 7 cases it was reached 
a normal weight. At the end of the treatment the end-
point concerning the weight was accomplished by 25 
out of 46 patients (i.e., 54.3%).
As far as the liver enzymes is concerned, Figure 
2 shows the percentage of abnormal values at BL, 
at mid-intervention (3M) and end-intervention (6M). 
All three liver enzymes significantly decrease during 
the treatment (see Table 3) and the reduction of 
abnormal values was elevated. The normalization was 
particularly evident for the ALT enzyme whose altered 
values reduced from 67% at baseline down to 11% 
after the treatment.
Table 3 summarizes results of the statistical 
analysis carried out in order to assess the effect of the 
treatment on anthropometric, clinical and metabolic 
parameters considered in this study.
Several parameters, i.e., BMI, waist circumference, 
waist-to-hip ratio, AST, ALT, GGT, LDL, HDL, TG, 
serum glucose, Tot-Chol/HDL, LDL/HDL, TG/HDL, AIP, 
HOMA, QUICKI, FLI and LAP, showed a significant 
improvement between baseline and end-treatment. 
Among parameters positively affected by the treatment 
after 6 mo, most of them, i.e., BMI, waist circumference, 
waist-to-hip ratio, AST, ALT, GGT, serum glucose, Tot-
Chol/HDL, LDL/HDL, HOMA, QUICKI, FLI and LAP (men) 
showed a significant improvement also after 3 mo from 
the start of the treatment.
In order to evaluate the efficacy of the approach 
proposed in this study for the management of NAFLD, 
the achievement of set end-points was evaluated. 
Figure 3 shows the percentage of patients that achieved 
the target, singularly for each end-points.
All criteria were achieved for at least 50% of 
patients. The percentage of success is particularly high 
(more than 80%) for steatosis, ALT, AST and GGT.
The intervention was also successful in increasing 
the percentage of participants carrying out physical 
activity on a regular basis (about 49% at baseline 
and 60% at end-intervention, Figure 4). Moreover, 
also people not able to carry out physical activity due 
to physical constraints declared their engagement 
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Table 1  Main characteristics of 46 patients recruited for the 
study
Parameter Value 
(mean ± SD or frequency)
Population n (%)
   Total 46
   M 29 (63%)
   F 17 (37%)
Age (yr)
   Range 26-71
   mean ± SD 47.5 ± 12
BMI (kg/m2)
   Range 18.9-45.3
   mean ± SD  29.3 ± 6.1
BMI (kg/m2)
   Obesity grade
   18.5-24.9 (normal weight) 23.90%
   25-29.9 (overweight) 43.50%
   30-34.9 (class Ⅰ obesity) 17.40%
   35-39.9 (class Ⅱ obesity)   8.70%
   ≥ 40 (class Ⅲ obesity)   6.50%
Waist circumference (cm)
   M  100.88 ± 12.97
   F  101.88 ± 15.07
Obesity central (Waist circumference)
   M (> 102 cm) 48.30%
   F (> 88 cm) 82.40%
Waist-to-hip ratio
   Android obesity
      M (≥ 1) 41.40%
      F (≥ 0.85) 70.60%
   Gynoid obesity
      M (≤ 0.94) 20.70%
      F (≤ 0.78)   0.00%
Components of MS2
   0 4 (8.7%)
   1 20 (43.5%)
   2 10 (21.7%)
   3   5 (10.9%)
   4   5 (10.9%)
   5 2 (4.3%)
Liver steatosis grade
   1 3 (6.5%)
   2 19 (41.3%)
   3 24 (52.2%)
MedDiet Score
   Range 21-41
   mean ± SD  28.4 ± 3.9
Physical activity
   No 24 (52.2%)
   Yes 22 (47.8%)
   Times1/wk
      1 6 (13%)
      2 7 (15.2%)
      3 7 (15.2%)
      > 3 2 (4.3%)
Smoking
   No 35 (76.1%)
   Ex 3 (6.5%)
   Yes 8 (17.4%)
1At least 30 min of moderate/intense activity; 2According to Alberti et al[39].
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in increasing their physical activity through simple 
daily activities indicated in the section concerning the 
counseling process.
Table 4 shows the correlations between steatosis 
grade and anthropometric, clinical and metabolic 
parameters considered in this study.
Only waist-to-hip ratio and HOMA correlated with 
steatosis grade both at baseline and at end-treatment. 
Some parameters, e.g., BMI, waist circumference, 
serum glucose and QUICKI, didn’t show any significant 
correlation at baseline but the correlation was ob-
served at end-treatment. Other parameters, e.g., 
Total Cholesterol, HDL, AST/ALT and PLr, showed a 
tendency only at the end- treatment.
Table 5 shows the correlations between BMI and 
anthropometric, clinical and metabolic parameters 
considered in this study.
Some parameters, i.e., waist circumference, MS, 
HOMA-Ir, QUICKI, Kotronen index, NAFLD liver fat 
score, and LAP (male) correlated with BMI both at 
baseline and at end-treatment. Some parameters, 
i.e., hip-to-waist ratio, Tot. Chol., HDL didn’t show any 
significant correlation at baseline but the correlation 
was observed at end-treatment. On the other hand, 
FLI and BARD, showed a significant correlation only at 
baseline. Correlation between BMI and steatosis grade 
was previously reported, while correlation between 
BMI and MedDiet score is significant but is available 
only at baseline.
DISCUSSION
Most recent advances in the management and treat-
ment of NAFLD show that a multifaceted approach, 
using a multidisciplinary team is likely to achieve the 
best outcome[40]. Combination of physical activity, 
medications, and dietetic interventions can be more 
effective than each prescription alone[24]. In addition, 
intervention tailored and aimed at encouraging self-
empowerment and behavioral change are regarded as 
essential for increasing adhesion to treatments[40].
This observational study is set in this research 
trend and was aimed at evaluating the effectiveness of 
a 6-mo multidisciplinary approach jointly carried out by 
a gastroenterologist and a nutritionist with counseling 
license for treating patients with NAFLD. The nutritional 
counseling was used as tool for encouraging patients 
to improve their lifestyle (MedDiet-based dietary habits 
and regular physical activity).
According to our results, the approach clearly 
demonstrated its effectiveness on reduction of NAFL 
severity, weight loss and anthropometric indexes as 
well as normalization of metabolic index and liver 
enzymes.
Some patients’ characteristics at baseline are of 
relevance for discussing the results obtained. Firstly, 
it is interesting to point out that the MedDiet score 
is similar to that reported by Kontogianni et al[21] 
(28.4 ± 3.9 in this study and 32.5 ± 5.0 in the other 
study). According to our results the MedDietScore was 
significantly and inversely correlated with steatosis 
grade (P = 0.044) (Table 4).
Also, a significant percentage of patients (about 
25%) had normal weight confirming that, even 
if positive energy balance and increased BMI sub-
stantially increase the risk of NAFLD, this latter may 
develop in individuals with normal BMI as well[41] e.g., 
as a consequence of an uncorrected lifestyle.
It is also interesting to underline that BMI and waist 
circumference does not correlate with NAFLD grade at 
baseline but correlation is significant at end-treatment 
for both parameters. At baseline, patients were also 
characterized by altered insulin resistance (Ir) and 
Table 2  Frequency of metabolic syndrome’ components in patients with metabolic syndrome
Component Hypertension Blood pressure TG HDL Serum glucose
n 12 6 12 7 8
TG: Triglycerides; HDL: High-density lipoprotein.
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Figure 2  Effect of the treatment on the normalization of liver enzymes. 
Normal values: < 40 U/L for AST, < 50 U/L for ALT, < 55 U/L for GGT. AST: 
Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-
glutamyl transferase.
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insulin sensitivity, respectively estimated by HOMA-
Ir and QUICKI, as could be expected considering 
that Ir is usually associated to NAFLD[12] and recently 
identified as the key aspect in the pathophysiology of 
both NAFLD and MS[42].
The reduction of NAFLD severity of patients is the 
main and relevant outcome of the treatment. In fact, 
the effects of MedDiet and increased physical activity, 
both associated or separated, have been investigated 
in several studies in terms of NAFLD-related indexes[37], 
hepatic enzymes[43], reduction of cardiovascular risk[44] 
or improvement in insulin sensitivity[45]. However, the 
present observational study is the first specifically 
examining effects of a multidisciplinary approach 
aimed at promoting the adherence to MedDiet and an 
active lifestyle directly on NAFLD severity.
According to Figure 3, in more than 80% of patients 
at least one grade reduction of NAFLD severity was 
observed. Our results confirm the positive outcomes of 
the study carried out by ryan et al[46] who observed a 
Table 3  Anthropometric, clinical and metabolic parameters at baseline, mid-intervention (3M) and end-intervention (6M) and 
results of the statistical analysis
Parameter mean ± SD, BL mean ± SD, 3M mean ± SD, 6M P value
BL vs  3M 3M vs  6M BL vs  6M
BMI (kg/m2)   29.3 ± 6.11   28.0 ± 6.21   27.5 ± 6.21 < 0.01a < 0.01a < 0.01a
Waist circumference (cm) 101.25 ± 13.63   97.50 ± 14.07   96.24 ± 13.64 < 0.01a < 0.01a < 0.01a
Hip-to-waist ratio   0.95 ± 0.08   0.94 ± 0.07   0.93 ± 0.08 < 0.01a < 0.01a < 0.01a
AST (U/L)   36.16 ± 21.11   28.73 ± 11.28   24.84 ± 10.70 < 0.01a < 0.01a < 0.01a
ALT (U/L)   65.66 ± 31.92   48.37 ± 33.44   37.33 ± 19.53 < 0.01a < 0.01a < 0.01a
GGT (U/L)   60.19 ± 61.43   41.35 ± 36.49   39.73 ± 35.36 < 0.01a 0.545 < 0.01a
FA (U/L)   81.48 ± 37.19   79.54 ± 32.04   80.04 ± 35.02 0.489 0.787 0.574
Total cholesterol (mg/dL) 215.24 ± 40.78 205.04 ± 41.75 207.18 ± 38.48  0.044a 0.598 0.097
LDL cholesterol (mg/dL) 137.70 ± 32.87 131.25 ± 35.88 130.16 ± 32.65 0.071 0.941  0.050a
HDL cholesterol (mg/dL)   49.72 ± 10.59   50.17 ± 11.64   53.09 ± 11.86 0.550 < 0.01a < 0.01a
TG (mg/dL) 133.39 ± 67.77 123.65 ± 71.31 118.24 ± 65.14 0.112 0.358  0.017a
Serum glucose (mg/dL)   98.33 ± 15.87   94.52 ± 13.07   95.76 ± 13.46 < 0.01a 0.133 < 0.01a
Chol Tot/HDL   4.50 ± 1.27   4.23 ± 1.07   3.95 ± 1.15  0.013a  0.010a < 0.01a
LDL/HDL   2.89 ± 0.95   2.67 ± 0.93   2.56 ± 0.84  0.028a  0.015a < 0.01a
TG/HDL   2.87 ± 1.76   2.66 ± 1.89   2.39 ± 1.66 0.152  0.037a < 0.01a
AIP   0.03 ± 0.25 -0.01 ± 0.23 -0.06 ± 0.25 0.097 0.089 < 0.01a
HOMA- IR (mU/L)   3.25 ± 1.96   2.96 ± 1.73   2.94 ± 1.67 < 0.01a 0.841 < 0.01a
QUICKI   0.33 ± 0.04   0.34 ± 0.04   0.34 ± 0.03 < 0.01a 0.330 < 0.017a
PLR 115.37 ± 46.60 109.89 ± 51.77 113.65 ± 43.77 0.195 0.281 0.816
NLR   1.98 ± 1.12   1.88 ± 1.10   1.79 ± 0.89 0.287 0.509 0.185
FLI   61.55 ± 26.76   50.54 ± 29.37   48.83 ± 31.01 < 0.01a 0.286 < 0.01a
Kotronen index (%)   6.05 ± 5.02   4.10 ± 2.22   3.92 ± 2.40 < 0.01a 0.277 < 0.01a
VAI   1.85 ± 1.17   1.55 ± 0.71   1.32 ± 0.65 0.011 0.010 < 0.01a
NAFLD Liver Fat Score   0.12 ± 1.63 -0.02 ± 1.42 -0.70 ± 1.20 0.418 < 0.01a < 0.01a
LAP (male)   48.41 ± 28.14   37.01 ± 19.95   33.18 ± 17.49 < 0.01a 0.166 < 0.01a
LAP (female)   84.15 ± 63.06   78.92 ± 70.51   74.13 ± 58.89 0.290 0.452 < 0.01a
BARD   1.09 ± 1.26   1.46 ± 1.17   1.37 ± 1.04  0.011a 0.486 0.091
NAFLD -2.29 ± 0.93 -2.13 ± 1.01 -2.28 ± 1.00  0.015a  0.032a 0.986
Values are expressed as mean ± SD. aP ≤ 0.05, significant difference. BL: Baseline; NAFLD: Non-alcoholic fatty liver disease; TG: Triglycerides; HDL: High-
density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase.
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
En
d-
po
in
t 
ac
hi
ev
em
en
t 
(%
)
Steatosis
grade
Weight Serum
glucose
Tot-Col LDL-Col HDL-Col Serum TG AST ALT GGT
80.4
54.3
50.0
67.4
58.7
52.2
71.7
87.0 89.1
91.3
Figure 3  Grade of success for parameters and measures included in the end-points. TG: Triglycerides; HDL: Highdensity lipoprotein; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase.
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Table 4  Correlation between steatosis grade and anthropometric, clinical and metabolic parameters considered in this study at 
baseline and at end-treatment
Parameter Grade 0 (n  = 9) Grade I (n  = 15) Grade 2 (n  = 18) Grade 3 (n  = 4) P  value
mean ± STD mean ± STD mean ± STD mean ± STD
BMI (kg/m2) BL -   30.19 ± 2.15 28.05 ± 6.47 30.11 ± 6.14 0.499
6M 23.39 ± 3.52   25.94 ± 5.60 31.36 ± 6.53 25.77 ± 1.14  0.013a
Waist circumference (cm) BL - 103.00 ± 1.73   96.05 ± 12.94 105.15 ± 13.91 0.122
6M   86.44 ± 11.98   90.73 ± 9.24 106.03 ± 12.64 94.88 ± 9.37 < 0.01a
Hip-to-waist ratio (-) BL -     0.94 ± 0.05   0.91 ± 0.08   0.98 ± 0.07  0.020a
6M   0.88 ± 0.06     0.91 ± 0.06   0.97 ± 0.08   0.93 ± 0.09 < 0.01a
Tot Chol (mg/dL) BL -   260.67 ± 27.21 210.95 ± 31.20 212.96 ± 46.24 0.266
6M 215.89 ± 39.78   196.27 ± 62.92 212.06 ± 34.35 154.75 ± 44.90 0.078
HDL (mg/dL) BL -   47.00 ± 3.46   52.05 ± 13.39 48.21 ± 8.39 0.532
6M 142.16 ± 33.53   130.60 ± 22.94 131.33 ± 35.27   96.25 ± 38.88 0.070
LDL (mg/dL) BL -   186.67 ± 37.63 133.52 ± 19.00 134.88 ± 37.05 0.119
6M   54.33 ± 12.97     53.73 ± 14.08   53.56 ± 10.74 45.75 ± 1.89 0.399
TG (mg/dL) BL -   134.00 ± 43.28 125.21 ± 42.18 139.79 ± 85.63 0.597
6M 100.22 ± 31.69   119.20 ± 40.40 138.22 ± 88.51   65.25 ± 42.94 0.807
AST BL -     0.72 ± 0.28   0.87 ± 0.33   0.95 ± 0.67 0.435
6M   0.55 ± 0.15     0.63 ± 0.19   0.67 ± 0.37   0.53 ± 0.17 0.641
ALT BL -     0.91 ± 0.20   1.32 ± 0.68   1.35 ± 0.64 0.419
6M   0.56 ± 0.14     0.79 ± 0.37   0.82 ± 0.50   0.67 ± 0.23 0.334
AST/ALT BL -     0.76 ± 0.15   0.71 ± 0.19   0.66 ± 0.20 0.276
6M   0.95 ± 0.15     0.76 ± 0.22   0.73 ± 0.26   0.78 ± 0.11 0.058
GGT BL -     58.67 ± 64.53   51.89 ± 54.69   42.21 ± 25.60 0.392
6M 17.00 ± 4.12     43.53 ± 25.67 44.39 ± 0.10 27.25 ± 0.50 0.147
Blood gluc. (mg/dL) BL -   96.67 ± 9.29   94.16 ± 15.71 101.83 ± 16.26 0.181
6M 88.00 ± 1.94   91.27 ± 7.33 104.33 ± 17.03 91.50 ± 8.19  0.018a
SM (n) BL -     2.67 ± 1.15   1.32 ± 1.00   2.17 ± 1.43 0.350
6M   1.44 ± 1.13     1.73 ± 1.28   2.28 ± 1.49   1.25 ± 0.50 0.415
Tot-Chol/HDL BL -     5.60 ± 1.03   4.29 ± 1.27   4.53 ± 1.26 0.637
6M   4.07 ± 0.84     3.84 ± 1.55   4.09 ± 0.94   3.41 ± 1.09 0.479
LDL/HDL BL -     4.03 ± 1.14   2.72 ± 0.82   2.88 ± 0.96 0.355
6M   2.70 ± 0.82     2.60 ± 0.90   2.54 ± 0.82   2.12 ± 0.91 0.333
TG/HDL BL -     2.83 ± 0.78   2.63 ± 1.36   3.07 ± 2.11 0.516
6M   1.92 ± 0.73     2.44 ± 1.25   2.79 ± 2.24   1.46 ± 1.02 0.698
AIP BL -     0.44 ± 0.11   0.37 ± 0.21   0.39 ± 0.29 0.983
6M   0.25 ± 0.19     0.34 ± 0.21   0.35 ± 0.27   0.08 ± 0.31 0.780
HOMA-IR (mU/L) BL -     2.77 ± 0.22   2.37 ± 1.37   4.01 ± 2.18  0.015a
6M   1.50 ± 0.84     2.47 ± 1.06   4.12 ± 1.71   2.67 ± 1.51 < 0.01a
QUICKI BL -     0.33 ± 0.00   0.35 ± 0.04   0.32 ± 0.03 0.082
6M   0.37 ± 0.05     0.34 ± 0.02   0.32 ± 0.02   0.34 ± 0.03 < 0.01a
PLR BL -   120.89 ± 28.83 107.31 ± 32.51 121.06 ± 57.08 0.467
6M   93.44 ± 22.18   106.95 ± 48.08 127.33 ± 47.95 122.70 ± 30.46 0.058
NLR BL -     1.36 ± 0.37   1.79 ± 0.80   2.21 ± 1.34 0.112
6M   1.32 ± 0.21     1.67 ± 1.08   2.21 ± 0.85   1.44 ± 0.50 0.097
FLI BL -   98.97 ± 0.30 98.84 ± 0.39 98.70 ± 0.75 0.612
6M 98.48 ± 0.72   98.79 ± 0.40 98.75 ± 0.67 97.08 ± 1.82 0.143
Kotronen index (%) BL -     4.63 ± 2.14   4.3 ± 2.0   7.6 ± 6.4  0.047a
6M   2.15 ± 0.83     3.5 ± 1.0   5.3 ± 3.2   3.1 ± 0.6  0.017a
VAI BL -     3.5 ± 1.8   1.9 ± 1.0   1.6 ± 1.1  0.041a
6M   1.44 ± 0.64     1.38 ± 0.65   1.29 ± 0.67     0.9 ± 0.67 0.224
NAFLD fat liver score BL -  -0.42 ± 0.9  -0.6 ± 1.1   0.7 ± 1.8  0.016a
6M   1.88 ± 0.71    -0.84 ± 0.78   0.07 ± 1.27  -0.99 ± 0.63 < 0.01a
LAP (male) BL -   52.00 ± 0.00   44.27 ± 19.98   50.51 ± 32.82 0.694
6M   25.67 ± 11.38     31.11 ± 14.62   42.38 ± 19.13   26.11 ± 22.32 0.386
LAP (female) BL -     72.10 ± 32.56   56.13 ± 31.50 130.21 ± 83.11 0.377
6M   24.42 ± 16.25     52.21 ± 23.70 109.22 ± 67.63 - 0.147
BARD BL -     2.33 ± 1.15   0.79 ± 1.08   1.17 ± 1.34 0.733
6M   1.89 ± 0.33     1.07 ± 1.03   1.56 ± 1.15   0.50 ± 1.00 0.192
NAFLD BL -    -3.41 ± 0.48  -2.25 ± 0.73  -2.17 ± 1,02 0.112
6M  -2.44 ± 0.93    -2.68 ± 0.87  -1.88 ± 1.07  -2.27 ± 0.91 0.144
MedDiet Score BL -   30.0 ± 3.0 29.6 ± 4.6 27.2 ± 3.1  0.044a
6M NA NA NA NA NA
aP ≤ 0.05, significant difference. NAFLD: Non-alcoholic fatty liver disease; TG: Triglycerides; HDL: High-density lipoprotein; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase.
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positive effect of MedDiet on NAFLD. However, results 
cannot be directly compared due to the different 
method used to assess NAFLD severity.
The treatment showed positive effects on anthro-
pometric indexes. In fact BMI decreased on average 
from 29.3 ± 6.11 to 27.5 ± 6.21, waist circumference 
decreased on average from 101.25 ± 13.63 to 96.24 
± 13.64 and hip-to-waist ratio decreased on average 
from 0.95 ± 0.08 to 0.93 ± 0.08 (Table 3). The 
improvement of previous anthropometric indexes is of 
relevance considering that all of them impact on CVD 
and MS related states and risks.
Excellent results of the treatment was confirmed 
also by the significant reduction of the Kotronen index 
(by 35% of the average and P < 0.01), the VAI (by 
28% of the average and P < 0.01), NAFLD liver fat 
score (by 18% of the average and P < 0.01) and FLI (by 
21% of the average and P < 0.01) (Table 3). Steatosis 
grade resulted significantly correlated with Kotronen 
index and NAFLD liver fat score both at baseline and 
end-treatment while correlation of steatosis grade 
with VAI was significant only at baseline. Absence 
of correlation at end-treatment could be due to the 
significant number of patients which showed regression 
of the disease. On the contrary the index FLI did not 
correlate with steatosis grade neither at baseline nor at 
end-treatment.
During the 6-mo of the treatment was also ob-
served an improvement of the lipid profile of several 
patients (Figure 3). In fact, considering mean values, it 
was observed a reduction of Tot-Chol (215.24 ± 40.78 
vs 207.18 ± 38.48), LDL (137.70 ± 32.87 vs 130.16 
± 32.65) and TG (133.39 ± 67.77 vs 118.24 ± 65.14) 
while an increase was observed for HDL (49.72 ± 
10.59 vs 53.09 ± 11.86) (Table 3).
The treatment had also positive effects on liver 
enzymes with improvements or normalization of AST 
(36.16 ± 21.11 at baseline and 24.84 ± 10.70 at end-
treatment), ALT (65.66 ± 31.92 at baseline and 37.33 
± 19.53 at end-treatment) and GGT (60.19 ± 61.43 at 
Table 5  Correlation between BMI and anthropometric, clinical and metabolic parameters considered in this study at baseline and at 
end-treatment
Parameter P  value Parameter P  value
Steatosis grade BL 0.499 TG/HDL BL 0.370
6M  0.013a 6M 0.416
Waist circumf. (cm) BL < 0.01a AIP BL 0.194
6M < 0.01a 6M 0.307
Hip-to-waist ratio (-) BL 0.231 HOMA-IR (mU/L) BL < 0.01a
6M  0.020a 6M < 0.01a
Tot Chol (mg/dL) BL 0.257 QUICKI BL < 0.01a
6M < 0.01a 6M < 0.01a
HDL (mg/dL) BL 0.255 PLR BL 0.213
6M < 0.01a 6M 0.645
LDL (mg/dL) BL 0.211 NLR BL 0.066
6M 0.768 6M 0.167
TG (mg/dL) BL 0.352 FLI BL < 0.01a
6M 0.229 6M 0.137
AST BL 0.244 Kotronen index (%) BL 0.038a
6M 0.093 6M < 0.01a
ALT BL 0.504 VAI BL 0.479
6M 0.154 6M 0.373
AST/ALT BL 0.195 NAFLD fat liver score BL < 0.01a
6M 0.114 6M < 0.01a
GGT BL 0.075 LAP (male) BL < 0.01a
6M 0.176 6M < 0.01a
MS (n) BL  0.025a LAP (female) BL 0.075
6M  0.025a 6M 0.176
Blood gluc. (mg/dL) BL 0.182 BARD BL < 0.01a
6M 0.142 6M 0.079
Tot-Chol/HDL BL 0.218 NAFLD BL 0.058
6M 0.090 6M 0.167
LDL/HDL BL 0.185 MedDiet Score BL  0.049a
6M 0.087 6M NA
aP ≤ 0.05, significant difference. TG: Triglycerides; HDL: High-density lipoprotein.
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Figure 4  Percentage of participants carrying out physical activity on a 
regular basis at baseline and at end-intervention. 
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baseline and 39.73 ± 35.36 at end-treatment) (Table 3 
and Figure 3). Of particular relevance was the effect on 
ALT with altered values reduced from almost 70% at 
baseline to just 10% at end-treatment. Normalization 
of values was significant also for AST (altered values at 
baseline were three-fold those at end treatment) and 
GGT (altered values were halved at end-treatment).
Positive effects of the MedDiet on liver enzymes 
were already observed by Fraser et al[43] in obese 
patients with type 2 diabetes and in the ATTICA study, 
that evaluated the prevalence of MS among over 3000 
Greek adults[47]. On the other hand it is interesting to 
point out that ryan et al[46] observed a positive effect 
of MedDiet on reduction in liver fat content (assessed 
with magnetic resonance imaging) but no significant 
differences in AST and ALT values were observed.
The treatment also showed positive effects on 
insulin resistance and insulin sensitivity: HOMA-Ir 
significantly reduce at end-treatment with respect 
to baseline (3.25 ± 1.96 vs 2.94 ± 1.67, P < 0.01) 
while QUICKI increase (0.33 ± 0.04 vs 0.34 ± 0.03). 
Considering the reduction observed for the NAFLD 
grade, this result was expected, as NAFLD worsens 
the state of Ir and may lead on to type 2 diabetes in 
the predisposed subjects[48]. Improvement of Ir was 
expected considering that it was already observed 
in previous studies as a consequence of treatment 
centered either on MedDiet[46] or increased physical 
activity[37].
In conclusions, outcomes of this study further 
strengthen the hypothesis that MedDiet and more 
active lifestyle can be considered a safe therapeutic 
approach for reducing risk and severity of NAFLD 
and related disease states such as MS and CVD. This 
suggests that the proposed approach, carried out 
by a multidisciplinary team composed of a gastro-
enterologist and a nutritionist with counseling license, 
may be proposed as a valid and recommended approach 
for improving the clinical profile of NAFLD patients.
Although this study does not allow to assess the 
effect of nutritional counseling, excellent results in 
terms end-points achievement (Figure 3) suggest that 
the adherence to the proposed approach was very 
successful. 
replication and improvement of the study design, 
by a control arm and a follow-up after the end-
treatment, are advisable to confirm the outcomes 
obtained so far and to assess the importance of 
multidisciplinary and counseling in modern approach 
for clinical management of NAFLD.
Limitations of the study
In this study we did not distinguish between simple 
fatty liver and NASH. In addition, despite Mr-S is 
considered gold standards for assessing the severity 
of NAFLD using non-invasive techniques, in this study 
was used US which is considered the preferred first-
line diagnostic procedure for imaging (EASL-EASD-
EASO, 2016). According to previous studies (inter alia 
Ghaemi et al[49], 2013) we also supported the diagnosis 
with US with serum biomarkers and scores.
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